Vascular endothelial growth factor‐targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma

Adult “translocation” renal cell carcinoma (RCC), bearing transcription factor E3 (TFE3) gene fusions at Xp11.2, is a recently recognized, unique entity for which prognosis and therapy remain poorly understood. In the current study, the authors investigated the effect of vascular endothelial growth factor (VEGF)‐targeted therapy in this distinct subtype of RCC.

[1]  I. Roberts,et al.  An adult Xp11.2 translocation renal carcinoma showing response to treatment with sunitinib. , 2011, Urologic oncology.

[2]  M. Rubin,et al.  Validation of a TFE3 Break-apart FISH Assay for Xp11.2 Translocation Renal Cell Carcinomas , 2011, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[3]  Wanling Xie,et al.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  T. Choueiri,et al.  A case of adult metastatic Xp11 translocation renal cell carcinoma treated successfully with sunitinib. , 2009, Clinical genitourinary cancer.

[5]  P. Camparo,et al.  Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  C. Porta,et al.  Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. , 2009, The Lancet. Oncology.

[7]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[8]  T. Choueiri,et al.  Optimizing recent advances in metastatic renal cell carcinoma , 2009, Current oncology reports.

[9]  Y. Ishikawa,et al.  Adult Xp11 Translocation Renal Cell Carcinoma Diagnosed by Cytogenetics and Immunohistochemistry , 2009, Clinical Cancer Research.

[10]  P. Casali,et al.  Response to Sunitinib Malate in Advanced Alveolar Soft Part Sarcoma , 2009, Clinical Cancer Research.

[11]  Karl J. Dykema,et al.  Renal Translocation Carcinomas: Clinicopathologic, Immunohistochemical, and Gene Expression Profiling Analysis of 31 Cases With a Review of the Literature , 2008, The American journal of surgical pathology.

[12]  A. Parwani,et al.  Renal cell carcinoma in a 33-year-old male with an unusual morphology and an aggressive clinical course: possible Xp11.2 translocation. , 2008, Pathology.

[13]  M. Ladanyi,et al.  Xp11 Translocation Renal Cell Carcinoma in Adults: Expanded Clinical, Pathologic, and Genetic Spectrum , 2007, The American journal of surgical pathology.

[14]  M. Picken,et al.  Xp11.2 translocation renal cell carcinoma with very aggressive course in five adults. , 2007, American journal of clinical pathology.

[15]  P. Argani,et al.  Xp11 translocation renal cell carcinoma: delayed but massive and lethal metastases of a chemotherapy-associated secondary malignancy. , 2007, Urology.

[16]  A. Olshen,et al.  Global gene expression profiling of PAX‐FKHR fusion‐positive alveolar and PAX‐FKHR fusion‐negative embryonal rhabdomyosarcomas , 2007, The Journal of pathology.

[17]  M. Ladanyi,et al.  TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. , 2007, Cancer research.

[18]  A. Pappo,et al.  Pediatric renal cell carcinoma: clinical, pathologic, and molecular abnormalities associated with the members of the mit transcription factor family. , 2006, American journal of clinical pathology.

[19]  M. Ladanyi,et al.  Translocation carcinomas of the kidney. , 2005, Clinics in laboratory medicine.

[20]  M. Ladanyi,et al.  Distinctive neoplasms characterised by specific chromosomal translocations comprise a significant proportion of paediatric renal cell carcinomas. , 2003, Pathology.

[21]  M. Ladanyi,et al.  Aberrant Nuclear Immunoreactivity for TFE3 in Neoplasms With TFE3 Gene Fusions: A Sensitive and Specific Immunohistochemical Assay , 2003, The American journal of surgical pathology.

[22]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[23]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[24]  A. Ravaud,et al.  Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  R. Motzer,et al.  Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[27]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.